Industry Verticals »

All Categories

Insights »

About TMR »

Next-Generation Immunotherapies Market

Next-Generation Immunotherapies Market (By Product/Therapy Type: Monoclonal Antibodies, Checkpoint Inhibitors, CAR-T Cell Therapy, Cancer Vaccines, Bispecific Antibodies, Antibody-Drug Conjugates, Cytokines & Immune Modulators, Oncolytic Virus Therapy; By Application: Cancer (Lung Cancer, Breast Cancer, Hematologic Malignancies, Colorectal Cancer, Melanoma, Prostate Cancer, Others), Autoimmune & Inflammatory Diseases, Infectious Diseases, Others; By Route of Administration: Intravenous, Subcutaneous, Oral; and by End-user) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2026-2036

Next-Generation Immunotherapies Market Outlook 2036

The global next-generation immunotherapies market was valued at USD 130.4 Billion in 2025 and is projected to reach USD 280.3 Billion by 2036, expanding at a CAGR of 7.2% from 2026 to 2036. The market is expected to witness strong growth as advances in TIL therapies, CAR-T therapies, bispecific antibodies, and other personalized immunotherapies expand cancer treatment options. Increasing R&D investments, advances in cell engineering, and the expansion of immunotherapies into earlier lines of treatment are expected to support market growth.

Market Size & Highlights

  • The next-generation immunotherapies market reached USD 130.4 Billion in 2025.
  • The market is estimated to reach USD 280.3 Billion by 2036.
  • The next-generation immunotherapies industry is anticipated to expand at a CAGR of 7.2% from 2026 to 2036.
  • Top companies operating in the market include Bristol-Myers Squibb, Roche, Merck & Co., Novartis, Johnson & Johnson, etc.
  • North America dominated the market in 2025, holding the largest revenue share of 42.9%.
  • By product/therapy type, the monoclonal antibodies segment held the largest market share of 49.5% in 2025

Next Generation Immunotherapies Market By Revenue

Analysts’ Viewpoint

The next-generation immunotherapies market is poised to experience robust growth owing to advances in cell therapy, bispecific antibodies, cancer vaccines and other forms of immunotherapy. Advances in immunotherapy are contributing to the increased commercial potential for immunotherapy, especially in hematologic malignancies and challenging solid tumors. FDA approval of additional CAR-T indications reflects the expanding clinical use of cellular immunotherapies. The FDA approval of an allogeneic regulatory T-cell-based immunotherapy in June 2026 demonstrates the diversification of technologies away from the traditional autologous CAR-T technology. From an industry point of view, pharmaceutical companies’ growing interest in bispecific antibodies and combination immunotherapy approaches is expected to intensify competition.

In recent times, there have been increasing efforts to improve efficacy, reduce toxicity, target a broader range of tumors, and simplify administration of these development programs. Manufacturing scalability remains a challenge, particularly for personalized therapies that require complex collection, processing, quality control, and administration. Financial issues, complicated administration, and safety issues are other major hurdles. Development in the areas of cell engineering, biomarker discovery, and precision oncology is anticipated to drive wider adoption of the technology. The future of the market looks positive, with further developments in the pipeline, convergence of technologies, partnerships, and increasing regulatory expertise contributing to growth.

Market Introduction

The next-generation immunotherapies market encompasses advanced therapeutic approaches designed to enhance the immune system’s ability to identify and eliminate disease-causing cells, particularly cancer cells. The market encompasses advanced technologies such as CAR-T cell therapy, TIL therapy, TCR-T cell therapy, bispecific antibodies, immune checkpoint inhibitors, cancer vaccines, and various other engineered immunotherapies. The expansion of these technologies across multiple indications is creating a dynamic market environment.

Hematological cancers have now emerged as an important application domain, whereas solid tumors constitute the main area of research and business interest. The latest advancements in cell engineering, antibody engineering, genetic modification, drug selection based on biomarkers, and manufacturing through automation have been instrumental in developing highly specialized products. It is anticipated that continued pharmaceutical investments, a growing therapeutic pipeline, and increasing demand for individualized treatment solutions are expected to drive market growth.

Attribute Detail
Next-Generation Immunotherapies Market Drivers
  • Rising Global Cancer Burden Driving Demand for Advanced Immunotherapy
  • Expanding Use of Precision Oncology and Biomarker-Guided Therapies

Rising Global Cancer Burden Driving Demand for Advanced Immunotherapy

Increased cancer incidence around the globe is giving rise to a high demand for efficacious treatment techniques, contributing to the increased demand for advanced immunotherapy approaches. As per the World Health Organization (WHO), approximately 20.6 million people are diagnosed with cancer every year globally, whereas the number of new cancer cases is projected to reach approximately 35 million by 2050 without effective preventive and treatment mechanisms.

WHO has also pointed out that the rising burden is due to the aging population, rising population, and changing exposures to carcinogens. According to the IARC, there were an estimated 20.6 million cases of cancer in the year 2024 and there will be 34.4 million projected cases of cancer in the year 2050. According to IARC, one in five people develops cancer during their lifetime, and one in nine men and one in 12 women die because of cancer, which shows the necessity for further development of treatments. WHO says that there has been a rise in the number of cancer cases in different parts of the world.

This sizable and growing patient base has spurred pharmaceutical companies to develop therapies that provide enhanced efficacy, longer disease control, and personalized treatments. The rising focus on CAR-T, TCR-T, TIL treatments, bispecific antibodies, and other immunotherapy platforms is thus providing strong support to the future growth of the next-generation immunotherapies market.

Expanding Use of Precision Oncology and Biomarker-Guided Therapies Accelerating Personalized Immunotherapy Adoption

The continuous increase in the use of personalized immunotherapy is becoming one of the key drivers in the growth of the next-generation immunotherapies market. Advances in genomic profiling, biomarker testing, molecular diagnostics, and precision oncology are enabling healthcare professionals to identify patients most likely to benefit from specific immunotherapeutic approaches. The American Society of Clinical Oncology (ASCO) states that more than 5,000 research abstracts/papers were presented or featured at the 2025 ASCO Annual Meeting, with a great deal of attention paid to diagnostics, immunotherapy, precision medicine and biomarker treatments, which shows importance of personalized cancer treatment in clinics.

As stated by the National Cancer Institute (NCI), biomarker testing is a major component of cancer treatment decision-making as tumors have their own unique genetic and molecular characteristics which determine their response to treatment. Increasing tumor profiling technology in oncology is resulting in greater availability of personalized immunotherapies and targeted immune-based treatments. As per an ASCO-sponsored study of advanced non-small cell lung cancer patients conducted in 2024, around 49.7% of patients in a cohort of 1,000 patients were not able to go forward with precision oncology due to issues with the availability of information regarding biomarker testing process, that indicating substantial scope for improved biomarker-testing access in the future as technology improves. This situation indicates that a large population could benefit from personalized therapy solutions in the future.

The healthcare sector is also seeing rising capital inflows into the fields of next-generation genome sequencing (NGS), molecular diagnostics, and AI-assisted clinical decision support, which are all part of the same ecosystem of precision medicine. Targeted cancer treatment methods such as CAR-T treatment, TCR-T treatment, tumor-infiltrating lymphocyte therapies, and treatments guided by biomarkers are being developed to be used based on particular features of the disease rather than through a more standardized approach. As precision oncology becomes more fully applied in standard cancer therapy, the demand for improved immunotherapy platforms is expected to increase as well, thus giving rise to beneficial opportunities for the participants in the market.

Attribute Detail
Next-Generation Immunotherapies Market Opportunities
  • Allogeneic & Off-the-Shelf Cell Therapies

Allogeneic and Off-the-Shelf Cell Therapies Creating a Scalable Opportunity in Immunotherapy

Allogeneic and off-the-shelf cell therapies hold significant potential for the next-generation immunotherapies market in that the use of pre-manufactured products will help reduce the time required to create patient-specific cells. According to statistics published by the European Society for Blood and Marrow Transplantation (EBMT), there have been 21,023 allogeneic hematopoietic cell transplants performed in 2024 at 688 centers in 53 countries, which is 2.6% higher than the data of 2023 and the highest number ever reported by EBMT in one year. Another figure of note is the 24.5% rise in 6,082 patients undergoing CAR-T therapy in 2024 compared to 2023.

As of January 2026, the U.S. Food and Drug Administration (FDA) states that around 50 gene and cell therapy products received approval from CBER in the last ten years. This implies the continuous development of regulatory approvals for advanced cell therapy methods. Also, in May 2026, a new guidance was provided by FDA, which gives more flexibility concerning the chemistry, manufacturing, and control requirements for gene and cell therapy products, facilitating the development and manufacturing of many products.

As per the clinical research indexed by the NIH, allogeneic CAR-T platforms are being developed as therapies that may be available more rapidly than patient-specific autologous treatments, as is done for autologous products. The advent of commercially available allogeneic cell therapy is one more factor favorable for these developments. Ryoncil is the first-ever allogeneic cell therapy product that has been approved by the FDA in the U.S. These innovations create opportunities for scalable manufacturing, faster treatment availability, greater production consistency, and broader patient access.

Monoclonal Antibodies Holds the Largest Share in the Product/Therapy Type Segment

Next Generation Immunotherapies Market By Type

Among the product/therapy type segment, Monoclonal Antibodies hold the dominant position and account for approximately 49.5% share of the total market due to their proven clinical usage, vast application potential, and consistent growth in the availability of anti-body treatments. As per the U.S. Food and Drug Administration (FDA), the Oncology Center of Excellence approved 89 oncology drug and biologic product submissions in 2024, which included 19 novel drug entities/biologics and 34 novel indications for drugs already approved. Other approvals have added more strength to the monoclonal antibody category.

According to the FDA, Daratumumab and Hyaluronidase-fihj was recently approved for a second time in November 2025, for use in adult patients with high-risk smoldering multiple myeloma; and pembrolizumab therapy received multiple approvals, including a variety of solid tumors. According to FDA, pembrolizumab was approved in 2025 in subcutaneous formulation. The wide range of indications, presence of existing products, and continued penetration into new patients make the monoclonal antibodies a commercially stable segment. The growing focus on the use of antibodies, including check point blocking antibodies and other antibody therapeutics, is expected to support the segment’s continued leading position. These factors, together, make the monoclonal antibodies the dominant therapy/product segment in the market segmentation provided.

Regional Outlook of Next-Generation Immunotherapies Market

Next Generation Immunotherapies Market By Region

Attribute Detail
Leading Region
  • North America

North America dominated the global next-generation immunotherapies market in 2025, accounting for approximately 42.9% of total market revenue, owing to the robust infrastructure in the field of oncology, early approvals by regulatory bodies, highly advanced cell-therapy facilities, and rapid adoption of novel cancer treatments. As per NCI, in the year 2025, there were estimated to be 2,041,910 new cancer cases and 618,120 cancer deaths in the United States, supporting demand for advanced immunotherapies. As per FDA, the U.S. cell and gene therapy landscape comprises several approved products; and CAR-T therapy, T cell therapy, and other cellular products have been increasingly used in cancer patients.

The FDA approved Lifileucel (Amtagvi) in February 2024 for the treatment of adults suffering from unresectable or metastatic melanoma, while Obecabtagene Autoleucel (Aucatzyl) was approved in November 2024 for the treatment of adult patients suffering from relapsed or refractory B-cell precursor acute lymphoblastic leukemia. These developments reflect the robust regulatory endorsement and increased clinical use of immunotherapy in North America.

Analysis of Key Players in Next-Generation Immunotherapies Market

The market includes major pharmaceutical companies and biotechnology firms competing across monoclonal antibodies, checkpoint inhibitors, CAR-T therapies, T-cell therapies, and bispecific antibodies. Bristol Myers Squibb is a major player in the cell therapy segment owing to its CAR-T products suite. Gilead Sciences is another strong competitor through Kite due to its existing CAR-T drugs like Yescarta and Tecartus. Novartis has a well-established presence in CAR-T therapies using Kymriah. Johnson & Johnson has strengthened its cell therapy portfolio through Carvykti in multiple myeloma. Regeneron Pharmaceuticals has strengthened its position in bispecific antibody therapies with FDA providing accelerated approval to Lynozyc in July 2025 for relapsed or refractory multiple myeloma. Iovance Biotherapeutics has a unique positioning in tumor infiltrating lymphocytes therapy following the FDA approval of Amtagvi in 2024.

T-cell receptor-based therapy has been proven to be effective as shown by the FDA’s approval of Tecelra in August 2024 for treatment of unresectable or metastatic synovial sarcoma. Competitive strength is generally gauged on the basis of effectiveness, range of indications, manufacturing capacity, and development of future scalable cellular and immune-based therapies.

Key Developments in Next-Generation Immunotherapies Market

  • In March 2026, Anixa Biosciences, Inc., a biotechnology company focused on cancer treatment and prevention, announced a presentation of its ovarian cancer CAR-T therapy clinical trial at the Society of Gynecologic Oncology Annual Meeting. The presentation covered the ongoing Phase 1 trial of lira-cel, an FSHR-targeted CAR-T therapy being developed with Moffitt Cancer Center for recurrent ovarian cancer, with enrollment focused on patients who had progressed after at least two prior therapies.
  • In December 2025, Gilead Sciences, Inc., presented encouraging Phase 1 results for KITE-753 and KITE-363, two investigational bicistronic CAR-T therapies targeting CD19 and CD20 in patients with relapsed/refractory large B-cell lymphoma. KITE-753 showed a 79% complete response rate among 14 CAR-T-naïve patients at the third dose level, supporting further development of dual-targeting CAR-T therapies designed to improve treatment response and reduce tumor escape.

Next-Generation Immunotherapies Market Snapshot

Attribute Detail
Size in 2025 USD 130.4 Billion
Forecast Value in 2036 USD 280.3 Billion
CAGR 7.2%
Forecast Period 2026-2036
Historical Data Available for 2021-2025
Quantitative Units USD Billion
Next-Generation Immunotherapies Market Analysis It includes segment analysis and regional level analysis. Qualitative analysis includes drivers, restraints, opportunities, key trends, value chain analysis and key trend analysis.
Competition Landscape
  • Competition Matrix
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Segmentation Product/Therapy Type
  • Monoclonal Antibodies
  • Checkpoint Inhibitors
  • CAR-T Cell Therapy
  • Cancer Vaccines
  • Bispecific Antibodies
  • Antibody-Drug Conjugates (ADCs)
  • Cytokines & Immune Modulators
  • Oncolytic Virus Therapy
Application
  • Cancer
    • Lung Cancer
    • Breast Cancer
    • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
    • Colorectal Cancer
    • Melanoma
    • Prostate Cancer
    • Others
  • Autoimmune & Inflammatory Diseases
  • Infectious Diseases
  • Others
Route of Administration
  • Intravenous
  • Subcutaneous
  • Oral
End-user
  • Hospitals
  • Specialty Clinics
  • Cancer Research Institutes
  • Ambulatory Surgical Centers
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • The Netherlands
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • ASEAN
  • Brazil
  • Mexico
  • Argentina
  • GCC Countries
  • South Africa
Companies Profiled
  • Bristol-Myers Squibb Company
  • Roche Holding AG
  • Merck & Co., Inc.
  • Novartis AG
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • Pfizer Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie Inc.
  • BioNTech SE
  • Moderna, Inc.
  • GlaxoSmithKline plc
  • Genmab A/S
  • Adaptimmune Therapeutics plc
  • Immunocore Holdings plc
  • Iovance Biotherapeutics, Inc.
  • Legend Biotech Corporation
  • Autolus Therapeutics plc
  • Other Prominent Players
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global next-generation Immunotherapies market in 2025?

The market was valued at USD 130.4 Billion in 2025

How big will the global next-generation Immunotherapies industry be in 2036?

The industry is projected to reach USD 280.3 Billion by 2036

What are the factors driving the next-generation Immunotherapies market?

Key drivers include the rising global cancer burden, which is increasing demand for advanced immunotherapies, and the expanding use of precision oncology and biomarker-guided therapies, which is accelerating personalized immunotherapy adoption.

What will be the CAGR of the global next-generation Immunotherapies market during the forecast period?

The CAGR is anticipated to be 7.2% from 2026 to 2036

Which region will account for a major share of the next-generation Immunotherapies sector during the forecast period?

North America is expected to account for the largest share from 2026 to 2036

Who are the prominent players in the global next-generation Immunotherapies market?

Bristol-Myers Squibb Company, Roche Holding AG, Merck & Co., Inc., Novartis AG, Johnson & Johnson, Gilead Sciences, Inc., Pfizer Inc., Amgen Inc., AstraZeneca PLC, Regeneron Pharmaceuticals, Inc., AbbVie Inc., BioNTech SE, Moderna, Inc., GlaxoSmithKline plc, Genmab A/S, Adaptimmune Therapeutics plc, Immunocore Holdings plc, Iovance Biotherapeutics, Inc., Legend Biotech Corporation, and Autolus Therapeutics plc among others.

  1. Preface
    • Market Definition and Scope
    • Market Segmentation
    • Key Research Objectives
    • Research Highlights
  2. Assumptions and Research Methodology
  3. Executive Summary: Global Next-Generation Immunotherapies Market
  4. Market Overview
    • Introduction
      • Segment Definition
      • Industry Evolution / Developments
    • Overview
    • Market Dynamics
      • Drivers
      • Restraints
      • Opportunities
    • Global Next-Generation Immunotherapies Market Analysis and Forecast, 2021-2036
      • Market Revenue Projections (USD Billion)
  5. Key Insights
    • Pipeline Analysis
    • Product Approval Analysis
    • Regulatory Landscape
    • Emerging Market Trends
    • Pricing Analysis
    • Reimbursement Landscape
    • Investment & Funding Landscape
    • M&A and Partnership Landscape
    • PESTLE Analysis
    • Porter’s Five Forces Analysis
    • Unmet Clinical Needs
    • Future Growth Outlook
  6. Global Next-Generation Immunotherapies Market Analysis and Forecast, by Product/Therapy Type
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Attractiveness Analysis, by Product/Therapy Type
  7. Global Next-Generation Immunotherapies Market Analysis and Forecast, by Application
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Attractiveness Analysis, by Application
  8. Global Next-Generation Immunotherapies Market Analysis and Forecast, by Route of Administration
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Attractiveness Analysis, by Route of Administration
  9. Global Next-Generation Immunotherapies Market Analysis and Forecast, by End-user
    • Introduction & Definition
    • Key Findings/Developments
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis, by End-user
  10. Global Next-Generation Immunotherapies Market Analysis and Forecast, by Region
    • Key Findings
    • Market Value Forecast, by Region, 2021-2036
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa
    • Market Attractiveness Analysis, by Region
  11. North America Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • U.S.
      • Canada
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
      • By Country/Sub-region
  12. U.S. Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  13. Canada Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  14. Europe Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • The Netherlands
      • Switzerland
      • Rest of Europe
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
      • By Country/Sub-region
  15. Germany Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  16. United Kingdom Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  17. France Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  18. Italy Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  19. Spain Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  20. The Netherlands Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  21. Switzerland Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  22. Rest of Europe Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  23. Asia Pacific Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • China
      • India
      • Japan
      • South Korea
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
      • By Country/Sub-region
  24. China Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  25. India Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  26. Japan Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  27. South Korea Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  28. Australia & New Zealand Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  29. Rest of Asia Pacific Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  30. Latin America Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
      • By Country/Sub-region
  31. Brazil Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  32. Mexico Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  33. Argentina Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  34. Rest of Latin America Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  35. Middle East & Africa Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Value Forecast, by Country/Sub-region, 2021-2036
      • GCC Countries
      • South Africa
      • Rest of Middle East & Africa
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
      • By Country/Sub-region
  36. GCC Countries Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  37. South Africa Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  38. Rest of Middle East & Africa Next-Generation Immunotherapies Market Analysis and Forecast
    • Introduction
      • Key Findings
    • Market Value Forecast, by Product/Therapy Type, 2021-2036
      • Monoclonal Antibodies
      • Checkpoint Inhibitors
      • CAR-T Cell Therapy
      • Cancer Vaccines
      • Bispecific Antibodies
      • Antibody-Drug Conjugates (ADCs)
      • Cytokines & Immune Modulators
      • Oncolytic Virus Therapy
    • Market Value Forecast, by Application, 2021-2036
      • Cancer
        • Lung Cancer
        • Breast Cancer
        • Hematologic Malignancies (Leukemia, Lymphoma, Multiple Myeloma)
        • Colorectal Cancer
        • Melanoma
        • Prostate Cancer
        • Others
      • Autoimmune & Inflammatory Diseases
      • Infectious Diseases
      • Others
    • Market Value Forecast, by Route of Administration, 2021-2036
      • Intravenous
      • Subcutaneous
      • Oral
    • Market Value Forecast, by End-user, 2021-2036
      • Hospitals
      • Specialty Clinics
      • Cancer Research Institutes
      • Ambulatory Surgical Centers
    • Market Attractiveness Analysis
      • By Product/Therapy Type
      • By Application
      • By Route of Administration
      • By End-user
  39. Competition Landscape
    • Market Player - Competition Matrix (By Tier and Size of Companies)
    • Market Share Analysis, by Company (2025)
    • Company Profiles
      • Bristol-Myers Squibb Company
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Roche Holding AG
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Merck & Co., Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Novartis AG
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Johnson & Johnson
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Gilead Sciences, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Pfizer Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Amgen Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • AstraZeneca PLC
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Regeneron Pharmaceuticals, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • AbbVie Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • BioNTech SE
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Moderna, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • GlaxoSmithKline plc
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Genmab A/S
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Adaptimmune Therapeutics plc
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Immunocore Holdings plc
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Iovance Biotherapeutics, Inc.
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Legend Biotech Corporation
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments
      • Autolus Therapeutics plc
        • Company Overview
        • Financial Overview
        • Product Portfolio
        • Business Strategies
        • Recent Developments

List of Tables

Table 01: Global Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 02: Global Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 03: Global Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 04: Global Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 05: Global Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 06: Global Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 07: North America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 08: North America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 09: North America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 10: North America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 11: North America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 12: North America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 13: U.S. Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 14: U.S. Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 15: U.S. Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 16: U.S. Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 17: U.S. Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 18: Canada Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 19: Canada Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 20: Canada Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 21: Canada Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 22: Canada Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 23: Europe Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 24: Europe Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 25: Europe Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 26: Europe Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 27: Europe Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 28: Europe Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 29: Germany Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 30: Germany Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 31: Germany Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 32: Germany Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 33: Germany Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 34: U.K. Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 35: U.K. Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 36: U.K. Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 37: U.K. Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 38: U.K. Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 39: France Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 40: France Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 41: France Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 42: France Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 43: France Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 44: Italy Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 45: Italy Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 46: Italy Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 47: Italy Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 48: Italy Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 49: Spain Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 50: Spain Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 51: Spain Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 52: Spain Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 53: Spain Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 54: The Netherlands Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 55: The Netherlands Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 56: The Netherlands Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 57: The Netherlands Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 58: The Netherlands Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 59: Switzerland Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 60: Switzerland Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 61: Switzerland Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 62: Switzerland Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 63: Switzerland Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 64: Rest of Europe Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 65: Rest of Europe Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 66: Rest of Europe Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 67: Rest of Europe Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 68: Rest of Europe Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 69: Asia Pacific Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 70: Asia Pacific Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 71: Asia Pacific Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 72: Asia Pacific Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 73: Asia Pacific Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 74: Asia Pacific Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 75: China Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 76: China Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 77: China Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 78: China Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 79: China Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 80: Japan Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 81: Japan Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 82: Japan Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 83: Japan Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 84: Japan Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 85: India Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 86: India Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 87: India Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 88: India Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 89: India Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 90: South Korea Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 91: South Korea Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 92: South Korea Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 93: South Korea Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 94: South Korea Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 95: Australia and New Zealand Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 96: Australia and New Zealand Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 97: Australia and New Zealand Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 98: Australia and New Zealand Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 99: Australia and New Zealand Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 100: Rest of Asia Pacific Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 101: Rest of Asia Pacific Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 102: Rest of Asia Pacific Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 103: Rest of Asia Pacific Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 104: Rest of Asia Pacific Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 105: Latin America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 106: Latin America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 107: Latin America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 108: Latin America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 109: Latin America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 110: Latin America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 111: Brazil Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 112: Brazil Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 113: Brazil Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 114: Brazil Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 115: Brazil Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 116: Mexico Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 117: Mexico Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 118: Mexico Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 119: Mexico Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 120: Mexico Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 121: Argentina Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 122: Argentina Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 123: Argentina Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 124: Argentina Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 125: Argentina Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 126: Rest of Latin America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 127: Rest of Latin America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 128: Rest of Latin America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 129: Rest of Latin America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 130: Rest of Latin America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 131: Middle East and Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 132: Middle East and Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 133: Middle East and Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 134: Middle East and Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 135: Middle East and Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 136: Middle East and Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Country/Sub-region, 2021 to 2036
Table 137: GCC Countries Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 138: GCC Countries Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 139: GCC Countries Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 140: GCC Countries Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 141: GCC Countries Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 142: South Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 143: South Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 144: South Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 145: South Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 146: South Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036
Table 147: Rest of Middle East and Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Product/Therapy Type, 2021 to 2036
Table 148: Rest of Middle East and Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Application, 2021 to 2036
Table 149: Rest of Middle East and Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Route of Administration, 2021 to 2036
Table 150: Rest of Middle East and Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by Cancer, 2021 to 2036
Table 151: Rest of Middle East and Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, by End-user, 2021 to 2036

List of Figures

Figure 01: Global Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 02: Global Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 03: Global Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 04: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Monoclonal Antibodies, 2021 to 2036
Figure 05: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Checkpoint Inhibitors, 2021 to 2036
Figure 06: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by CAR-T Cell Therapy, 2021 to 2036
Figure 07: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Cancer Vaccines, 2021 to 2036
Figure 08: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Bispecific Antibodies, 2021 to 2036
Figure 09: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Antibody-Drug Conjugates (ADCs), 2021 to 2036
Figure 10: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Cytokines & Immune Modulators, 2021 to 2036
Figure 11: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Oncolytic Virus Therapy, 2021 to 2036
Figure 12: Global Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 13: Global Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 14: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Cancer, 2021 to 2036
Figure 15: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Autoimmune & Inflammatory Diseases, 2021 to 2036
Figure 16: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Infectious Diseases, 2021 to 2036
Figure 17: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Others, 2021 to 2036
Figure 18: Global Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 19: Global Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 20: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Intravenous, 2021 to 2036
Figure 21: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Subcutaneous, 2021 to 2036
Figure 22: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Oral, 2021 to 2036
Figure 23: Global Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 24: Global Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 25: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Hospitals, 2021 to 2036
Figure 26: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Specialty Clinics, 2021 to 2036
Figure 27: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Cancer Research Institutes, 2021 to 2036
Figure 28: Global Next-Generation Immunotherapies Market Revenue (USD Billion), by Ambulatory Surgical Centers, 2021 to 2036
Figure 29: Global Next-Generation Immunotherapies Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 30: Global Next-Generation Immunotherapies Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 31: North America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 32: North America Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 33: North America Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 34: North America Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 35: North America Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 36: North America Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 37: North America Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 38: North America Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 39: North America Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 40: North America Next-Generation Immunotherapies Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 41: North America Next-Generation Immunotherapies Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 42: U.S. Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 43: U.S. Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 44: U.S. Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 45: U.S. Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 46: U.S. Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 47: U.S. Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 48: U.S. Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 49: U.S. Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 50: U.S. Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 51: Canada Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 52: Canada Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 53: Canada Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 54: Canada Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 55: Canada Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 56: Canada Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 57: Canada Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 58: Canada Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 59: Canada Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 60: Europe Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 61: Europe Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 62: Europe Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 63: Europe Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 64: Europe Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 65: Europe Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 66: Europe Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 67: Europe Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 68: Europe Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 69: Europe Next-Generation Immunotherapies Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 70: Europe Next-Generation Immunotherapies Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 71: Germany Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 72: Germany Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 73: Germany Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 74: Germany Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 75: Germany Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 76: Germany Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 77: Germany Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 78: Germany Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 79: Germany Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 80: U.K. Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 81: U.K. Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 82: U.K. Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 83: U.K. Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 84: U.K. Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 85: U.K. Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 86: U.K. Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 87: U.K. Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 88: U.K. Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 89: France Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 90: France Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 91: France Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 92: France Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 93: France Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 94: France Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 95: France Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 96: France Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 97: France Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 98: Italy Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 99: Italy Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 100: Italy Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 101: Italy Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 102: Italy Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 103: Italy Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 104: Italy Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 105: Italy Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 106: Italy Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 107: Spain Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 108: Spain Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 109: Spain Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 110: Spain Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 111: Spain Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 112: Spain Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 113: Spain Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 114: Spain Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 115: Spain Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 116: The Netherlands Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 117: The Netherlands Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 118: The Netherlands Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 119: The Netherlands Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 120: The Netherlands Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 121: The Netherlands Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 122: The Netherlands Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 123: The Netherlands Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 124: The Netherlands Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 125: Switzerland Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 126: Switzerland Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 127: Switzerland Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 128: Switzerland Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 129: Switzerland Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 130: Switzerland Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 131: Switzerland Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 132: Switzerland Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 133: Switzerland Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 134: Rest of Europe Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 135: Rest of Europe Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 136: Rest of Europe Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 137: Rest of Europe Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 138: Rest of Europe Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 139: Rest of Europe Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 140: Rest of Europe Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 141: Rest of Europe Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 142: Rest of Europe Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 143: Asia Pacific Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 144: Asia Pacific Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 145: Asia Pacific Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 146: Asia Pacific Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 147: Asia Pacific Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 148: Asia Pacific Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 149: Asia Pacific Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 150: Asia Pacific Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 151: Asia Pacific Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 152: Asia Pacific Next-Generation Immunotherapies Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 153: Asia Pacific Next-Generation Immunotherapies Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 154: China Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 155: China Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 156: China Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 157: China Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 158: China Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 159: China Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 160: China Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 161: China Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 162: China Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 163: Japan Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 164: Japan Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 165: Japan Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 166: Japan Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 167: Japan Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 168: Japan Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 169: Japan Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 170: Japan Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 171: Japan Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 172: India Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 173: India Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 174: India Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 175: India Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 176: India Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 177: India Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 178: India Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 179: India Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 180: India Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 181: South Korea Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 182: South Korea Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 183: South Korea Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 184: South Korea Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 185: South Korea Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 186: South Korea Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 187: South Korea Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 188: South Korea Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 189: South Korea Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 190: Australia and New Zealand Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 191: Australia and New Zealand Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 192: Australia and New Zealand Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 193: Australia and New Zealand Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 194: Australia and New Zealand Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 195: Australia and New Zealand Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 196: Australia and New Zealand Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 197: Australia and New Zealand Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 198: Australia and New Zealand Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 199: Rest of Asia Pacific Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 200: Rest of Asia Pacific Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 201: Rest of Asia Pacific Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 202: Rest of Asia Pacific Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 203: Rest of Asia Pacific Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 204: Rest of Asia Pacific Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 205: Rest of Asia Pacific Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 206: Rest of Asia Pacific Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 207: Rest of Asia Pacific Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 208: Latin America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 209: Latin America Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 210: Latin America Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 211: Latin America Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 212: Latin America Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 213: Latin America Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 214: Latin America Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 215: Latin America Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 216: Latin America Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 217: Latin America Next-Generation Immunotherapies Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 218: Latin America Next-Generation Immunotherapies Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 219: Brazil Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 220: Brazil Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 221: Brazil Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 222: Brazil Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 223: Brazil Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 224: Brazil Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 225: Brazil Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 226: Brazil Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 227: Brazil Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 228: Mexico Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 229: Mexico Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 230: Mexico Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 231: Mexico Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 232: Mexico Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 233: Mexico Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 234: Mexico Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 235: Mexico Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 236: Mexico Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 237: Argentina Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 238: Argentina Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 239: Argentina Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 240: Argentina Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 241: Argentina Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 242: Argentina Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 243: Argentina Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 244: Argentina Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 245: Argentina Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 246: Rest of Latin America Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 247: Rest of Latin America Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 248: Rest of Latin America Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 249: Rest of Latin America Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 250: Rest of Latin America Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 251: Rest of Latin America Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 252: Rest of Latin America Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 253: Rest of Latin America Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 254: Rest of Latin America Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 255: Middle East and Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 256: Middle East and Africa Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 257: Middle East and Africa Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 258: Middle East and Africa Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 259: Middle East and Africa Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 260: Middle East and Africa Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 261: Middle East and Africa Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 262: Middle East and Africa Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 263: Middle East and Africa Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 264: Middle East and Africa Next-Generation Immunotherapies Market Value Share Analysis, by Country/Sub-region, 2025 and 2036
Figure 265: Middle East and Africa Next-Generation Immunotherapies Market Attractiveness Analysis, by Country/Sub-region, 2026 to 2036
Figure 266: GCC Countries Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 267: GCC Countries Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 268: GCC Countries Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 269: GCC Countries Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 270: GCC Countries Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 271: GCC Countries Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 272: GCC Countries Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 273: GCC Countries Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 274: GCC Countries Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 275: South Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 276: South Africa Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 277: South Africa Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 278: South Africa Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 279: South Africa Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 280: South Africa Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 281: South Africa Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 282: South Africa Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 283: South Africa Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036
Figure 284: Rest of Middle East and Africa Next-Generation Immunotherapies Market Value (USD Billion) Forecast, 2021 to 2036
Figure 285: Rest of Middle East and Africa Next-Generation Immunotherapies Market Value Share Analysis, by Product/Therapy Type, 2025 and 2036
Figure 286: Rest of Middle East and Africa Next-Generation Immunotherapies Market Attractiveness Analysis, by Product/Therapy Type, 2026 to 2036
Figure 287: Rest of Middle East and Africa Next-Generation Immunotherapies Market Value Share Analysis, by Application, 2025 and 2036
Figure 288: Rest of Middle East and Africa Next-Generation Immunotherapies Market Attractiveness Analysis, by Application, 2026 to 2036
Figure 289: Rest of Middle East and Africa Next-Generation Immunotherapies Market Value Share Analysis, by Route of Administration, 2025 and 2036
Figure 290: Rest of Middle East and Africa Next-Generation Immunotherapies Market Attractiveness Analysis, by Route of Administration, 2026 to 2036
Figure 291: Rest of Middle East and Africa Next-Generation Immunotherapies Market Value Share Analysis, by End-user, 2025 and 2036
Figure 292: Rest of Middle East and Africa Next-Generation Immunotherapies Market Attractiveness Analysis, by End-user, 2026 to 2036

Copyright © Transparency Market Research, Inc. All Rights reserved

Next-Generation Immunotherapies Market

Buy This ReportBuy Now